STOCK TITAN

Stryker receives FDA clearance for Incompass Total Ankle System

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)

Streamlining total ankle replacement with data-driven implants and surgical flexibility

PORTAGE, Mich.--(BUSINESS WIRE)-- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker’s Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement.

Stryker's Incompass® Total Ankle System integrates the technologies of the Inbone® and Infinity® systems into a single, comprehensive solution.

Stryker's Incompass® Total Ankle System integrates the technologies of the Inbone® and Infinity® systems into a single, comprehensive solution.

“Incompass reflects our commitment to redefining what’s possible in total ankle replacement,” said Adam Jacobs, vice president and general manager of Stryker’s Foot & Ankle business. “By building on decades of clinical experience and leveraging extensive data insights, we’re setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence.”

Incompass incorporates Adaptis® Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans¹ and 100,000 clinical cases.¹ It also offers a broad range of implant and instrumentation options to support patient-specific care.

Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company’s Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time.

About Stryker

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.

Copyright © 2025 Stryker
Content ID: FA-INCO-PRESS-2016296

References:
1. Based on internal data as of 5/1/2025.

Media contact

Sampson Public Relations Group

Andrea Sampson

President/CEO asampson@sampsonprgroup.com

Source: Stryker

Stryker Corp

NYSE:SYK

SYK Rankings

SYK Latest News

SYK Stock Data

144.12B
361.26M
5.38%
79.94%
1.24%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PORTAGE